Background Severely immunocompromised patients are at risk for prolonged or relapsed
Coronavirus Disease 2019 (COVID-19), leading to increased morbidity and mortality. We …

COVID-19 in immunocompromised patients is difficult to treat. SARS-CoV-2 interaction with
the host immune system and the role of therapy still remains only partly understood. There …

Potential conflicts of interest. P. LW reports personal fees from Gilead, Pfizer, F2G, and MSD
and meeting sponsorship from Dynamiker, Bruker, and Launch outside the submitted work …

Background Monoclonal antibodies (mAbs) that target severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) are predominantly less effective against Omicron variants …

The aim of this study was to describe the outcomes of targeted COVID-19 treatments in
immunocompromised patients with asymptomatic or mild COVID-19 during the period of …

Background There is growing evidence that antibody responses play a role in the resolution
of SARS-CoV-2 infection. Patients with primary or secondary antibody deficiency are at …

Immunocompromised patients still experience unpredictable courses of COVID-19, despite
that effective vaccines and drugs against SARS-CoV-2 are now available. Antiviral …

Another recent publication reported success with a combination of monoclonal antibodies, 7
days of remdesivir, and 5 days of nirmatrelvir/ritonavir [2]. Influenced by the report from …

Because prolonged viral replication of SARS-CoV-2 is increasingly being recognized
among immunocompromised patients, subacute or chronic COVID-19 pneumonia can …

Background Most patients with SARS-CoV-2 are non-infectious within 2 weeks, though viral
RNA may remain detectable for weeks. However there are reports of persistent SARS-CoV-2 …